A Phase I Study of HyperAcute-Renal (HAR) Immunotherapy In Patients With Metastatic Renal Cell Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2017
At a glance
- Drugs Renal cancer vaccine-NewLink Genetics (Primary)
- Indications Renal cancer
- Focus Adverse reactions
- Sponsors NewLink Genetics Corporation
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
- 20 Sep 2016 Planned number of patients changed from 20 to 18.
- 20 Sep 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Oct 2016.